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Abstract Calcitonin gene-related peptide (CGRP)-con-
taining nerves are closely associated with cranial blood
vessels. CGRP is the most potent vasodilator known in
isolated cerebral blood vessels. CGRP can induce migraine
attacks, and two selective CGRP receptor antagonists are
effective in the treatment of migraine attacks. It is therefore
important to investigate its mechanism of action in patients
with migraine. We here investigate the effects of intra-
venous human alpha-CGRP (haCGRP) on intracranial
hemodynamics. In a double-blind, cross-over study, the
effect of intravenous infusion of haCGRP (2 lg/min) or
placebo for 20 min was studied in 12 patients with
migraine without aura outside attacks. Xenon-133 inhala-
tion SPECT-determined regional cerebral blood ﬂow
(rCBF) and transcranial Doppler (TCD)-determined blood
velocity (Vmean) in the middle cerebral artery (MCA), as
well as the heart rate and blood pressure, were the outcome
parameters. No change of rCBF was observed at the end of
infusion [1.2% ± 1.7 with haCGRP, vs. -1.6% ± 3.1
with placebo (mean ± SD)] (P = 0.43). Vmean in MCA
decreased to 13.5% ± 3.6 with haCGRP versus
0.6% ± 1.8 with placebo (P\0.005). Since rCBF was
unchanged, this indicates a dilation of the MCA. haCGRP
induced a decrease in MAP (12%) (P\0.005) and an
increase in heart rate (58%) (P\0.0001). CGRP dilates
cerebral arteries, but the effect is so small that it is unlikely
to be the only mechanism of CGRP-induced migraine.
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Introduction
Based on animal research showing calcitonin gene-related
peptide (CGRP) in perivascular nerves [1] and a strong
vasodilator effect of CGRP on cerebral blood vessels [2], a
role for CGRP in the pathogenesis of migraine pain was
ﬁrst suggested by reports of increased CGRP in external
jugular venous blood during migraine attacks [3–5]. In one
recent study, there was, however, no increase of CGRP [6].
More solid evidence was presented in a study which
demonstrated that, CGRP infused intravenously in patients
with migraine was able to induce a vascular type headache
in great majority of patients and in some patients this
headache fulﬁlled all diagnostic criteria for migraine
without aura [7]. The ﬁnal proof of the involvement of
CGRP in migraine mechanisms was provided by two phase
II clinical trials [8, 9], demonstrating signiﬁcant efﬁcacy of
the speciﬁc CGRP antagonists, BIBN4096BS [10] and
MK0974 [9]. Thus, CGRP is not only able to induce
attacks, but it seems to be continuously important
throughout the entire migraine attack. CGRP is one of the
most potent dilators of isolated cerebral arteries known
today [2, 11], but possible species differences make it
difﬁcult to predict the effect of CGRP in the human cere-
bral circulation. Although the effect of CGRP on the
cerebral circulation has been studied in normal subjects
[12], it is important to study it also in patients with
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attacks are induced by CGRP [7]. The aim of the present
study was therefore to investigate the cerebral hemo-
dynamic effects of CGRP in patients with migraine outside
of attack.
Patients and methods
Patients
Twelve patients with migraine (11 females, 1 male; mean
age 39.5 years, range 31–47 years; mean weight 69.7 kg,
range 51–89 kg) were included. All suffered from migraine
without aura according to criteria of the International
Headache Society [13]. The subjects were not allowed to
take medication, coffee, tea, alcohol or tobacco for 12 h
before the study, and they were not allowed to take a
triptan 24 h or ergotamine 48 h before the study.
Exclusion criteria were as follows: use of any kind of
daily medication including prophylactic headache therapy
but excluding oral contraceptives; pregnancy or breast-
feeding; excessive use of analgesics or alcohol; serious
somatic or psychiatric disorders; ischaemic heart disease;
a supine systemic blood pressure more than 160/90 or less
than 110/75 mmHg at entry of study.
Patients were informed that they were free to withdraw
at any time and all gave written informed consent. The
study was approved by the local ethics committees of
Copenhagen and Copenhagen County (KA 96054) and
complied with the Declaration of Helsinki.
Design and procedure
The patients with migraine were studied outside of attacks.
The study used a double-blind, placebo-controlled cross-
over design. Subjects were randomized to receive 2 lg/min
human aCGRP (haCGRP; Clinalfa, Switzerland) or pla-
cebo (0.9% NaCl) infused intravenously for 20 min on
2 days separated by at least 1 week. The dose was chosen
as the highest tolerated dose (because of blood pressure
reduction) based on reports in the literature [14, 15].
Patients were randomly assigned by computer (Med.
Stat, version 2.12). Randomization and preparation of
study drugs was done by medical staff, who were not
involved in the study. Five patients started with placebo
and seven with haCGRP. This quota was chosen by the
computer and not known before the study. The effective-
ness of blinding was not estimated.
When subjects arrived at the laboratory, a cannula
(Viggo Venﬂon, 1.4 mm) was placed in the right cubital
vein for haCGRP/placebo infusion. Baseline values of
mean maximal blood velocity (Vmean) in the middle
cerebral artery (MCA), regional cerebral blood ﬂow
(rCBF), blood pressure, heart rate and pCO2 were recorded
after 30 min of rest in the supine position in a quiet room.
Then, haCGRP or placebo was infused intravenously for
20 min by a volumetric pump (Braun Perfuser). Vmean,
blood pressure, heart rate and end tidal pCO2 were recor-
ded every 10 min during and after infusion until 80 min
after start of the haCGRP infusion. rCBF was measured
again during the last 5 min of infusion and at 75–80 min
after start of haCGRP/placebo infusion. At every record-
ing, it was noticed if volunteers were ﬂushing and
information about headache presence, intensity (measured
on a 0–10 scale) and characteristics were obtained before,
during and after the infusions. The results concerning
headache response have been published elsewhere [7].
Methods
rCBF was measured with a highly sensitive, brain-dedi-
cated, fast-rotating, single photon emission computerized
tomograph (Tomomatic 232). Each study lasted 4.5 min. A
mixture of atmospheric air and
133Xenon was rebreathed
during the ﬁrst 1.5 min through a closed system from a 4-L
reservoir (740 Mbq/L). During the last 3 min, the
133Xenon
mixture was expired against atmospheric air. rCBF was
recorded simultaneously in two slices positioned 50 and
90 mm above and parallel to the orbito-meatal plane (OM).
Each slice was 16 mm thick and the distance between
the centers of slices was 40 mm. The full width half maxi-
mum resolution of the instrument is about 16 mm in the
horizontal plane. rCBF was calculated according to Celsis
et al. [16].
A ﬁxed matrix of regions of interest was superimposed
on the rCBF picture. The shape and size were ﬁtted to the
outlines on the brain excluding extracranial ﬂow. Regional
mean values were calculated within the predeﬁned regions
of interest. The matrix was divided into regions of interest
representing the hemispheric rCBF regions and the
vascular territories of supply by the anterior-, middle- and
posterior cerebral arteries. The maximum whole body
radiation was approximately 0.6 mSV per rCBF measure-
ment [17].
Time averaged mean of the maximal blood velocity
(Vmean) in MCA at the usual headache side was measured
with transcranial Doppler (TCD) ultrasonography (2 MHz,
Multidop X Doppler: DWL, Sipplingen, Germany). A
mean of four consecutive values of Vmean was taken (each
representing the mean value of typically four to ﬁve heart
beats automatically calculated by the computer). Positions
of the measurements were reproduced from day to day by
recording the position in relation to the angle and distance
relative to the orbito-meatal line. Blood pressure and heart
rate were measured with an automatic inﬂatable arm cuff
152 J Headache Pain (2008) 9:151–157
123(Omega 1400, Invivo Research Laboratory, New York,
USA). Simultaneously, with each rCBF and TCD mea-
surement, the end expiratory pCO2 was recorded by means
of a capnograph (Datex OY, CD 101).
Statistics
Hemodynamic responses are given as mean and standard
deviation(±SD).Differencesinbloodvelocity,rCBF,blood
pressure,heartrateandpCO2overtimewithinthegroupwere
analyzed with analysis of variance (MANOVA, Statgraph-
ics 7.0), and changes were then located with a multiple
range test (Conﬁdence intervals, Statgraphics 7.0).
Differences in the delta values (baseline—the last
measurement during infusion and baseline—the last mea-
surement during the study) in Vmean, rCBF, blood pressure,
heart rate and pCO2 between the effect of haCGRP and the
effect of placebo were tested with a paired t test (Stat-
graphics 7.0). In all tests, P\0.05 was considered
statistically signiﬁcant.
Results
During CGRP infusion, two volunteers experienced a
substantial decrease in blood pressure (70/50 and 65/25,
respectively) causing the infusion to be terminated ahead of
time. Signs and symptoms were pallor, cold sweat, stomach
ache, nausea and palpitation. The situation was restored
after placing the volunteers in head-down tilt for 7 and
20 min, respectively. No rCBF and TCD measurements
were taken during this time period, and therefore, results
from these two volunteers were excluded from the calcu-
lations below.
Changes in end tidal pCO2
End-tidal pCO2 decreased signiﬁcantly over time when
volunteers were treated with haCGRP (P\0.0001) but not
when treated with placebo (P\0.26, MANOVA). The
pCO2 decrease at the last measurement during infusion was
-4.0% ± 0.8% when treated with haGCRP versus
0.7% ± 1.0% when treated with placebo (P\0.05, paired
t test). The peak decrease in end-tidal pCO2 induced by
haCGRP (-6.8% ± 2.6%) occurred at 25 min, 5 min after
end of infusion.
Transcranial Doppler measurements
The TCD examination was performed on the side of usual
migraine. The following data for Vmean in MCA are
corrected for changes in pCO2 according to Markwalder
et al. [18]:
VmeanðkorrÞ ¼VmeanðmeasÞexp 0:04 pCO2ðBasalÞ  pCO2ðnÞ
 
:
Vmean changed signiﬁcantly over time when patients
were treated with haCGRP (P\0.0001, MANOVA), but
not when treated with placebo (P = 0.26, MANOVA). At
the last measurement during infusion, 15 min after its
beginning, Vmean compared to baseline was -13.5% ±
11.4 when treated with hCGRP, versus 0.6% ± 5.6 when
treated with placebo (P\0.005, paired t test). At the end
of the in-hospital period (75 min after start of the infusion),
there was no difference between the two groups (P = 0.97,
paired t test) (Fig. 1, Table 1). There was a positive
correlation between DVmean and DMABP (r = 0.703,
P\0.05).
Regional cerebral blood ﬂow
All data have been corrected for changes in pCO2:
rCBF(korr) = rCBF(meas) 9 exp(0.04(pC02(Basal) - pCO2(n)).
For comparison of Vmean and rCBF, we calculated rCBF in
the territory of MCA, the artery used for TCD examination.
Area-weighted data from the OM + 50 mm and
OM + 90 mm were used for the results given below.
There was no change over time neither when patients
were treated with haCGRP (P = 0.26) nor when they were
treated with placebo (P = 0.88, MANOVA). During
infusion, rCBF compared to baseline was +1.2% ± 5.5
when treated with haCGRP versus -1.6% ± 9.8 when
treated with placebo. The difference between CGRP and
placebo was not signiﬁcant (P = 0.43, paired t test). Fur-
thermore, no signiﬁcant difference between CGRP and
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Fig. 1 The effect of hCGRP (2 lg/min) for 20 min and the effect of
placebo on the mean velocity (Vmean) in middle cerebral artery
(squares) and the regional cerebral blood ﬂow (rCBF) (triangles)i n
the territory of the middle cerebral artery (MCA) used for transcranial
Doppler examination. X-axis: time from start of infusion (min),
y-axis: changes in percent of baseline. Vmean (squares) decreased
-13.5% ± 3.6 compared to baseline with hCGRP treatment versus
0.6% ± 1.8 with placebo treatment (P\0.0001). After 75 min, there
was no difference between the two groups (P = 0.97). No change of
rCBF (triangles) was observed at the end of infusion (P = 0.43) or at
the end of study period (P = 0.12)
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123placebo was found at the end of the study period
(P = 0.12, paired t test) (Fig. 1, Table 2).
The absolute rCBF data and the rCBF data with pCO2
correction concerning the MCA area relevant for TCD
examination are given in Table 2. There was also no sig-
niﬁcant difference in pCO2-uncorrected rCBF between
CGRP and placebo during (P = 0.78, paired t test) or after
the infusion (P = 0.357, paired t test). There was a nega-
tive correlation between DrCBF(MCA) and DMABP (r =
-0.654, P\0.05). rCBF during haCGRP infusion was not
signiﬁcantly different in any territory or at any time point.
Blood pressure
The mean arterial blood pressure (MABP) decreased sig-
niﬁcantly over time when patients were treated with
haCGRP (P\0.0001), but not when they were treated
with placebo (P = 0.48, MANOVA). The maximal
decrease occurred at the last measurement during infusion
(20 min after start of infusion) and amounted to -12.3% ±
8.1% with haCGRP treatment versus +2.4% ± 5.9% with
placebo treatment (P\0.005, paired t test). MABP had
normalized at the end of the study period (80 min from
start of infusion) (P = 0.49) (Table 3). Both systolic and
diastolic blood pressures decreased during infusion of
CGRP compared to that during infusion of placebo
(P\0.05).
Heart rate
When patients were treated with haCGRP, heart rate
increased signiﬁcantly over time (P\0.0001, MANOVA),
but not when they were treated with placebo (P = 0.44,
MANOVA). The peak increase in heart rate after haCGRP
treatment occurred 20 min after start of infusion reaching
58.1% ± 22.7% versus 1.9% ± 5.58% with placebo
treatment (P\0.0001, paired t test). Heart rate after
haCGRP treatment was still different from that after pla-
cebo treatment at the end of the study period (P\0.005,
paired t test) (Table 3).
Other signs
Flushing after haCGRP treatment was pronounced and
appeared only in the face, neck and upper chest. It appeared
from 10 min (time of ﬁrst observation) after start of the
Table 1 The maximum mean blood velocity (Vmean) in the middle cerebral artery (MCA)
Time (min) Vmean in MCA (cm/s)
No pCO2 correction Corrected for pCO2 changes
CGRP Placebo CGRP Placebo CGRP% Placebo%
0 81.6 (10.7) 79.9 (12.3) 81.6 (10.7) 79.9 (12.3) 0 0
15–20 66.9 (13.5)* 79.5 (12.4) 70.7 (14.2)* 80.3 (12.7) -13.5 (11.4)* 0.6 (5.6)
75–80 76.6 (9.9) 77.4 (12.7) 80.6 (11.3) 79.2 (13.6) -0.7 (11.6) -0.9 (6.4)
Values within parentheses represent the standard deviation (SD)
Data is shown with and without pCO2 correction according to Markwalder et al. [18]
The pCO2-corrected data is shown as absolute data and in percent change from baseline (P\0.001)
* Signiﬁcant changes compared with baseline
Table 2 Regional cerebral blood ﬂow rCBF in the MCA territory recorded 50 and 90 mm above the orbitomeatal plane (OM)
Cerebral blood ﬂow (ml blood/100 g/min)
Time (min) MCA (OM 50 + OM 90) in the territory used for TCD examination
No pCO2 correction Corrected for pCO2 changes
Absolute data Absolute data Data in % of baseline
CGRP Placebo CGRP Placebo CGRP Placebo
0 70.8 (13.7) 67.7 (9.3) 70.8 (13.7) 67.7 (9.3) 0 0
15–20 66.8 (9.4) 65.3 (11.6) 71.1 (10.5) 66.7 (11.4) 1.2 (1.7) -1.6 (3.1)
75–80 69.3 (7.9) 65.0 (9.8) 72.8 (8.7) 66.7 (10.4) 4.2 (3.0) -1.6 (2.8)
Values within parentheses represent the standard deviation (SD)
Data is shown with and without pCO2 correction according to Markwalder et al. [18]
The pCO2-corrected data is shown as absolute data and in percent change from baseline (P\0.001)
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123infusion of haCGRP in all patients until median 70 min
after start of infusion (range 20–80 min). There was no
ﬂushing when the patients were treated with placebo. The
median headache during infusion of haCGRP was 1 versus
0 in the placebo-treated group (P\0.01). During the fol-
lowing 11 h, all patients experienced headache after
haCGRP treatment versus the one after placebo treatment
(P\0.001). The median headache score was 4 after
haCGRP treatment and 0 after placebo treatment. For
details, see [7].
Discussion
The main ﬁnding of the present study was that CGRP-
infusion dilated the MCA in patients with migraine, while
cerebral blood ﬂow remained unchanged. The dose of
2 lg/min of CGRP was chosen from the literature in which
the same dose of 545 pmol/min was given in healthy
volunteers without any reported adverse events [14]. In
another study, up to 25 lg CGRP was given as an intra-
venous bolus injection and all subjects had facial ﬂushing
[15]. The dose of 2 lg/min for 20 min is probably the
maximally tolerated dose of CGRP in patients with
migraine, since it resulted in a substantial decrease of
MABP and a marked increase in heart rate. Two subjects
were near fainting and had to be withdrawn. In healthy
volunteers, a dose of 1.5 lg/min was used without adverse
events apart from ﬂushing and without any effect on mean
blood pressure [12]. It remains uncertain whether the
stronger circulatory response in the present study was
exclusively due to the higher dose or whether patients with
migraine are more sensitive to CGRP. After 20 min infu-
sion at 1.5 lg/min, the mean plasma level was 340 pmol/L
in healthy volunteers [12]. It can be calculated from these
results that the plasma level would be 450 pmol/L in our
patients with migraine. The EC50 for CGRP for the dilatory
effect on human pial arteries is 500 pmol/L [19]. The dose
of CGRP used in the present study thus resulted in a plasma
level very near to the EC50 for cerebral arteries in vitro.
The blinding of the present study can be criticized. Signs
(increased heart rate) and symptoms (facial ﬂushing and
feeling of warmth) during CGRP infusion made it difﬁcult
to keep the study completely blinded. However, the present
design is the best one available, because no technique is
available to disguise such symptoms.
An interesting ﬁnding of the present study is the sig-
niﬁcant reduction of blood velocity (13.5% decrease) in the
MCA, but rCBF remained unchanged during intravenous
haCGRP-infusion. A reduced velocity in an artery, with
unchanged regional blood ﬂow in its territory of supply,
reﬂects dilation [20]. The relative diameter change can be
roughly estimated from the relation: ﬂow = mean velocity
multiplied by the cross-sectional area of the artery (2pr
2).
When the ﬂow is constant, velocity is a function of the
reciprocal value of r
2 and Va/Vb = rb
2/ra
2 [20]. We can thus
estimate from the change in mean velocity that the
haCGRP infusion caused a 7.5% increase in MCA diam-
eter corresponding to 17% increase of its cross sectional
area.
aCGRP infused in a considerably lower dose (0.6 lg/
min) did not change MCA velocity or rCBF in healthy
volunteers [21], while the dose of 1.5 lg/min in volunteers
dilated the MCA (9% increase in diameter) to the same
extent as in the present study [12]. The dilatation of MCA
in the present study could, theoretically, be due to cere-
brovascular autoregulation secondary to decreased blood
pressure. However, conduction arteries like MCA do nor-
mally only autoregulate due to blood pressure changes to a
much lesser extent than arterioles (for review, see [22]). A
positive correlation (r = 0.7, P\0.05) between changes
in MCA and changes in MABP seems to support this
possibility. However, this correlation could also reﬂect that
MCA and systemic circulation vary in parallel. In healthy
volunteers, using a slightly lower CGRP dose of 1.5 lg/
min, blood pressure was unchanged but MCA dilated to the
Table 3 The mean arterial blood pressure (MABP), systolic and diastolic blood pressure (mmHg) and heart rate (bpm) after CGRP and placebo
treatment
Blood pressure (mmHg) Heart rate (bpm)
Time (min) MABP Systolic BP Diastolic BP
CGRP Placebo CGRP Placebo CGRP Placebo CGRP Placebo
0 87.8 (9.6) 91.6 (9.5) 117.0 (11.1) 119.0 (12.6) 73.2 (9.5) 77.9 (9.4) 63.0 (6.0) 64.4 (7.2)
15 78.0 (7.5)* 90.0 (9.2) 110.7 (9.6) 117.2 (12.5) 61.7 (7.8) 76.4 (8.7) 92.9 (10.2)* 63.8 (6.8)
20 76.9 (10.1)* 93.5 (8.3) 112.2 (13.3) 123.9 (11.6) 59.3 (9.1) 78.3 (7.6) 98.9 (11.2)* 65.5 (7.1)
75 86.5 (9.2) 91.4 (8.7) 117.6 (12.0) 121.9 (13.4) 71.0 (8.9) 76.2 (7.2) 76.1 (7.0)* 62.9 (6.0)
80 85.3 (9.2) 91.3 (9.9) 116.4 (13.2) 123.3 (11.3) 69.7 (8.4) 75.3 (9.7) 75.3 (7.7)* 64.4 (5.3)
Values within parentheses represent ±standard deviation (±SD)
* P\0.05
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123same extent as in the present study [12]. This strongly
indicates that MCA dilation is a direct effect of CGRP.
In rat MCA, using the in vitro-pressurized arteriographic
model, luminal CGRP was without any dilating effect,
whereas abluminal CGRP dilated the artery [23]. This
indicated that CGRP was unable to cross the blood–brain
barrier in rat MCA. In contrast, both in patients with
migraine (Fig. 1) and in healthy volunteers [12], a dilation
of MCA was observed. Theoretically, CGRP could act on
an endothelial receptor, but this is unlikely because the
CGRP antagonist BIBN4096BS could not block the effect
on MCA in man [12]. Furthermore, in man, the calcitonin
receptor-like receptor (CLR) and receptor activity-modi-
fying protein (RAMP) are located mainly in the muscular
layer of the human MCA [24]. In the endothelium, there
was only a minor amount of CLR and largely absent
RAMP1 [24]. There is thus no CGRP receptor (CLR plus
RAMP1) on the endothelium. The present results with a
dilation of MCA could indicate that the blood–brain barrier
to CGRP in the MCA is less tight in man than in rats,
possibly related to the large difference in size.
In healthy volunteers, dilation of MCA was accompa-
nied by a modest (14%) increase in rCBF [12], whereas in
the present study, in patients with migraine, a 5% increase
in rCBF was not statistically signiﬁcant (Fig. 1). The
discrepancy may be due to random variation. Altered
cerebrovascular reactivity in patients with migraine com-
pared to controls is another possibility. The decrease of
mean MABP from 88 to 77 mmHg observed in the present
study could also be a factor if autoregulation was disturbed
by CGRP.
In patients with subarachnoid hemorrhage, a CGRP-
infusion concomitant with intravenous ﬂuid to correct any
drop in blood pressure resulted in a dilation of the MCA on
the vasospasm side [25]. Blood pressure was unchanged
while heart rate and cardiac output were increased and total
peripheral resistance was decreased [25]. In two studies in
man [14, 15], an increase in noradrenaline in plasma was
observed after CGRP. We found in the present study a
decrease in mean blood pressure and an increase in heart
rate as would be expected after administration of a potent
vasodilator such as CGRP.
In conclusion, the potent endogenous migraine-inducing
molecule CGRP resulted in a dilation of MCA and
unchanged rCBF. CGRP can thus most likely cross the
blood–brain barrier to some extent in the large human
cerebral arteries. The vasodilator effect on these arteries is
in our opinion, however, so small that it is unlikely to be
the only mechanism of CGRP-induced migraine observed
in our patients with migraine [7].
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